2nd Quarter - Report

VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED

Firm
Client
Income
—
Expenses
$480,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Issues related to Camp Comprehensive Tax Reform draft (no specific bills); Issues related to the Orphan Drug Tax Credit (no specific bills)

LobbyistCovered position, as disclosed
RACHEL WHITEFORD MACK —
MICHAEL MATTOON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Health Issues HCR

Issues related to regulatory reforms and drug development under the Energy & Commerce Committee's 21st Century Cures initiative (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions)

LobbyistCovered position, as disclosed
RACHEL WHITEFORD MACK —
MICHAEL MATTOON —
SAMANTHA VENTIMIGLIA —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 460 (113th)

Medicare/Medicaid MMM

H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions).

LobbyistCovered position, as disclosed
RACHEL WHITEFORD MACK —
MICHAEL MATTOON —
SAMANTHA VENTIMIGLIA —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE

Bills named: S. 1365 (113th), H.R. 2827 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.